25.07.2022 • NewsArkemaCoatingMergers & Acquisitions (M&A)

Arkema to Buy Mexico’s Polimeros Especiales

French specialty chemicals producer Arkema has announced it will acquire privately owned Mexican company Polimeros Especiales, a producer of high performance waterborne resins for applications in architectural and decorative paints, textiles, pressure sensitive adhesives and construction.

A key manufacturer of emulsions with a regional focus, with 230 employees, Polimeros Especiales had sales of $40 million in 2021.

Arkema said the acquisition is in line with its expansion plans for the Coating Solutions business segment, especially for the solvent-free waterborne segment in growing markets and in low-volatile organic compound solutions.

Waterborne counts among the Paris-based company’s key solvent-free technologies, together with powder, ultraviolet/light emitting diode/electron beam and high-solid systems.

With the acquisition of Polimeros Especiales, Arkema will develop new positions in the Mexican market, said Manuel Garcia, the company’s general manager for Mexico. “The acquisition will ensure continuous strong support to our customers and will enable Arkema to broaden its product offering locally,” he added.

Author: Dede Williams, Freelance Journalist

© Shutterstock/CK Foto
© Shutterstock/CK Foto

Company

Logo:

Arkema

420 rue d’Estienne d’Orves
92705 Colombes Cedex
France

Company contact







Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.